MADRIGAL PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Cash and Cash Equivalents, Period Increase (Decrease) of $129.48 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-13
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $135.67M, a 1161.78% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$21.84M, a 608.19% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was $10.75M.
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-09-30 was $4.30M.
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $129.48M, a 587.31% increase from fiscal 2016.
- MADRIGAL PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $18.84M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $135.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $113.83M derived: sum of 2 quarters · filed 2018-03-13 | $129.48M 10-K · filed 2018-03-13 | |
| 2017-09-30 | -$21.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$6.18M 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $15.65M 10-Q · filed 2017-08-10 | |||
| 2016-12-31 | $10.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $15.05M derived: sum of 2 quarters · filed 2018-03-13 | $18.84M 10-K · filed 2018-03-13 | |
| 2016-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $8.09M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $3.79M 10-Q · filed 2017-08-10 | |||
| 2011-06-30 | -$5.42M 10-Q · filed 2011-08-04 | |||
| 2010-06-30 | -$1.54M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |